|Bid||28.910 x 600|
|Ask||28.920 x 700|
|Day's Range||28.745 - 29.040|
|52 Week Range||24.540 - 29.930|
|PE Ratio (TTM)||380.13|
|Earnings Date||Apr 25, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.84|
Edwards Lifesciences, Medtronic, Boston Scientific and Abbott Laboratories are duking it out for a share of the fast-growing heart-valve replacement market.
Stock Monitor: CHF Solutions Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 18, 2018 / Active-Investors.com has just released a free research report on Boston Scientific Corp. (NYSE: BSX ). If ...
San Bruno-based nVision makes a microcatheter device used to screen for ovarian cancer and was founded by a 32-year-old female CEO who was honored last year as a distinguished alumnus of the Harker School in San Jose. She had raised only $17 million in venture funding before the sale.
Boston Scientific's (BSX) MedSurg business is likely to deliver an encouraging show in Q1 on the back of a strong endoscopy, driven by biliary, hemostasis, EndoChoice and Symetis buyouts.
The '550 patent was the only Edwards patent that Boston Scientific was found to infringe in the March 2017 German District Court litigation between the companies and is also the sole basis of Edwards' infringement action against Boston Scientific in Ireland. While Edwards has the right to appeal the EPO's decision, Boston Scientific believes the Edwards patent revocation will have a positive impact on both suits.
Surbhi Sarna decided she wanted to start a woman's health company after she suffered from an ovarian cyst so painful she passed out at age 15. Now she is 32, and her company is being bought by Boston Scientific.
MARLBOROUGH, Mass., April 16, 2018 /PRNewswire/ -- Boston Scientific (BSX) today announced that it has acquired nVision Medical Corporation, a privately-held company focused on women's health. Ovarian cancer is the fifth leading cause of cancer death among women.
The WATCHMAN platform is expected to experience a strong quarter on consistent global momentum as Boston Scientific's (BSX) multiple market development efforts continue to push for growth.
On April 6, 2018, Abbott Laboratories (ABT) was trading at a forward PE (price-to-earnings ratio) of 20.1x, while its PE was 57.6x. A lower forward estimate compared to the current PE represents analysts’ expectations that a company will generate higher earnings over the next 12 months.
On April 5, 2018, Abbott Laboratories (ABT) ended the trading day at $59.86 per share. The stock registered a rise of ~0.67% in its stock price compared to its previous day’s close. For more details, read Abbott Laboratories Traded at a 52-Week High after Posting Strong 4Q17 Results.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting BSX. Over the last one-month, outflows of investor capital in ETFs holding BSX totaled $15.80 billion.
Abbott Laboratories (ABT) showed an impressive performance in 2017 despite a challenging macroeconomic environment and big-ticket acquisitions. The company reported strong 2017 results on January 24, 2018, and it has secured a number of product approvals and reimbursement approvals since then, strengthening its market position.
On March 19, 2018, Abbott Laboratories (ABT) announced that it had received reimbursement approval for its MitraClip device in Japan. MitraClip is a minimally invasive procedure for patients suffering from MR (mitral regurgitation) who are at high risk of open surgery.
From medical device firms to small biotech stocks, the healthcare sector has been hit hard over the last few weeks. With that, the recent patch of lower returns could be seen as huge buying opportunity for healthcare stocks for patient investors. There are all sorts of healthcare stocks that dabble in the medical devices sector, but none can compete with Boston Scientific Corporation (NYSE:BSX) in the heart disease sector.
NEW YORK, NY / ACCESSWIRE / April 5, 2018 / Shares of Loxo Oncology were gaining heavily in Wednesday trading after the company announced that it would be presenting interim results of its Phase 1 clinical ...
Should Investors Be Interested in Varian Medical Systems? Varian Medical Systems’ (VAR) HyperArc is an end-to-end, high-definition, intracranial radiotherapy solution. Since the launch of this radiotherapy solution in 4Q16, the company has secured 57 orders, of which 19 were placed in 1Q18.
On March 23, 2018, Edwards Lifesciences (EW) announced that it won its dispute with Boston Scientific (BSX) over US Patent 8992608. The USPTO (US Patent and Trademark Office) decided in favor of Edwards in an inter partes review filed by Boston Scientific against Edwards for its TAVR (transcatheter aortic valve replacement) technology, finding all the related claims against Edwards to be invalid.